Clinical Trials Browser

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Completed

73 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

56 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitation

167 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

NCT06690541 2024-11-15

COMLORLA

Not yet recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04127110 2024-11-05

ALKALINE

Phase 2 Active not recruiting

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06282874 2024-02-28

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4 Not yet recruiting

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05167500 2023-03-30

LORLAPULM

Completed

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasm Metastasis

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms